The LoDoCo2 trial found a reduced cardiovascular risk with low-dose colchicine in patients with chronic coronary disease. In this substudy, attenuation of pericoronary adipose tissue did not differ ...

Colchicine may be used with caution to manage flare-ups of crystal-induced arthritis among patients with severe chronic kidney disease, with dosage modifications and careful monitoring required.

Colchicine, a widely available gout medication, has received FDA approval to be used in low dose to prevent cardiovascular events in patients with proven coronary disease. The approval to use low dose ...

An exploratory analysis of the LoDoCo2 (Low-Dose Colchicine 2) randomized, controlled, double-blind trial found that daily therapy with a low dose of colchicine was associated with lower incidences of ...

Please provide your email address to receive an email when new articles are posted on . Benefits of low-dose colchicine were consistent in men over a median follow-up period of 28.6 months. Due to low ...

Taking low-dose colchicine daily may slow the progression of a common acquired gene mutation found in the blood of older adults that can lead to certain blood cancers and increased risk of ...

Please provide your email address to receive an email when new articles are posted on . Patients with elevated levels of high-sensitivity C-reactive protein are at risk for CV events. Low-dose ...

NEW YORK — New insights into colchicine's disruption of the pathway that contributes to arterial inflammation and new clinical studies of the drug could pave the way toward greater use of the ...

BASEL, Switzerland—Low-dose colchicine doesn’t significantly reduce MACE in patients who have had a nonsevere ischemic stroke or high-risk TIA, according to the results of the CONVINCE trial. Through ...

A drug used to treat gout could reduce the risk of a heart attack or stroke, according to a new study. Researchers found colchicine - an inexpensive drug used to treat the painful type of arthritis - ...